Site Overlay

Lest we Forget: The Darker Side of the Hypocholesterolemic Statin Drugs

Michael W Whitehouse, Desley E Butters

School of Medicine, Griffith University, Gold Coast Qld, AUSTRALIA.

Pharmacognosy Communications,2018,8,1,2-7.
DOI:10.5530/pc.2018.1.2
Published:January-2018
Type:Original Article

ABSTRACT

Cholesterol-lowering statin drugs have been over-sold to the medical profession and over-prescribed by physicians, without due concern for their long-term disabling side-effects. These include acute renal failure, development of cataracts, diabetes, liver dysfunction and disabling myopathy. Most were predictable and have been well-documented: yet there has been little reduction in statin usage. The situation is made worse by more recent a) claims for off-label efficacy e.g. as anti-inflammatory agents and b) availability in some countries (e.g. UK) as over-the-counter medications. [1] Is it now time to carefully reconsider the need for such over-prescribing, with the promise of yet more to come (OTC availability, the ‘polypill’)?

Key words: Statins, Adverse effects, Cholesterol, Coenzyme Q, Dolichol, Polyisoprenoids.

Copyright © 2021 Pharmacognosy Communications. All Rights Reserved. | Catch Sketch by Catch Themes
Scroll Up